{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:04:32Z","timestamp":1787843072950,"version":"build-2784847793"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40273-024-01453-0","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T15:45:58Z","timestamp":1731685558000},"page":"271-282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USA"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5657-5733","authenticated-orcid":false,"given":"Xiaomo","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff Jianfei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"issue":"11","key":"1453_CR1","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/jnci\/djab079","volume":"113","author":"YT Lee","year":"2021","unstructured":"Lee YT, Wang JJ, Luu M, et al. The mortality and overall survival trends of primary liver cancer in the United States. J Natl Cancer Inst. 2021;113(11):1531\u201341. https:\/\/doi.org\/10.1093\/jnci\/djab079.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"1453_CR2","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1038\/s12276-020-00527-1","volume":"52","author":"E Kim","year":"2020","unstructured":"Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52(12):1898\u2013907. https:\/\/doi.org\/10.1038\/s12276-020-00527-1.","journal-title":"Exp Mol Med"},{"issue":"9","key":"1453_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005904","volume":"96","author":"P Golabi","year":"2017","unstructured":"Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 2017;96(9): e5904. https:\/\/doi.org\/10.1097\/MD.0000000000005904.","journal-title":"Medicine (Baltimore)"},{"issue":"5 Suppl. 1","key":"1453_CR4","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","volume":"127","author":"G Fattovich","year":"2004","unstructured":"Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl. 1):S35-50. https:\/\/doi.org\/10.1053\/j.gastro.2004.09.014.","journal-title":"Gastroenterology"},{"key":"1453_CR5","unstructured":"Cancer facts & figures 2023. American Cancer Society. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2023-cancer-facts-figures.html. Accessed 16 Apr 2024."},{"key":"1453_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acr.2020.10.001","volume":"149","author":"S Chidambaranathan-Reghupaty","year":"2021","unstructured":"Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1\u201361. https:\/\/doi.org\/10.1016\/bs.acr.2020.10.001.","journal-title":"Adv Cancer Res"},{"issue":"2","key":"1453_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.14218\/JCTH.2023.00356","volume":"12","author":"Y Abboud","year":"2024","unstructured":"Abboud Y, Ismail M, Khan H, et al. Hepatocellular carcinoma incidence and mortality in the USA by sex, age, and race: a nationwide analysis of two decades. J Clin Transl Hepatol. 2024;12(2):172\u201381. https:\/\/doi.org\/10.14218\/JCTH.2023.00356.","journal-title":"J Clin Transl Hepatol"},{"issue":"4","key":"1453_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4251\/wjgo.v13.i4.197","volume":"13","author":"MC Guan","year":"2021","unstructured":"Guan MC, Wang MD, Liu SY, et al. Early diagnosis and therapeutic strategies for hepatocellular carcinoma: from bench to bedside. World J Gastrointest Oncol. 2021;13(4):197\u2013215. https:\/\/doi.org\/10.4251\/wjgo.v13.i4.197.","journal-title":"World J Gastrointest Oncol."},{"issue":"3","key":"1453_CR9","doi-asserted-by":"publisher","first-page":"pkad034","DOI":"10.1093\/jncics\/pkad034","volume":"7","author":"B McMahon","year":"2023","unstructured":"McMahon B, Cohen C, Brown RS Jr, et al. Opportunities to address gaps in early detection and improve outcomes of liver cancer. JNCI Cancer Spectr. 2023;7(3):pkad034. https:\/\/doi.org\/10.1093\/jncics\/pkad034.","journal-title":"JNCI Cancer Spectr."},{"issue":"1","key":"1453_CR10","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1038\/s41598-024-54945-6","volume":"14","author":"L Huang","year":"2024","unstructured":"Huang L, Kang D, Zhao C, Liu X. Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Sci Rep. 2024;14(1):4327. https:\/\/doi.org\/10.1038\/s41598-024-54945-6.","journal-title":"Sci Rep"},{"issue":"1","key":"1453_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1186\/s12885-023-10955-7","volume":"23","author":"B Zhang","year":"2023","unstructured":"Zhang B, Shi X, Cui K, et al. Real-world practice of conversion surgery for unresectable hepatocellular carcinoma: a single center data of 26 consecutive patients. BMC Cancer. 2023;23(1):465. https:\/\/doi.org\/10.1186\/s12885-023-10955-7.","journal-title":"BMC Cancer"},{"issue":"15","key":"1453_CR12","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.23.02745","volume":"42","author":"JD Gordan","year":"2024","unstructured":"Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. J Clin Oncol. 2024;42(15):1830\u201350. https:\/\/doi.org\/10.1200\/JCO.23.02745.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1453_CR13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1053\/j.gastro.2021.12.276","volume":"162","author":"GL Su","year":"2022","unstructured":"Su GL, Altayar O, O\u2019Shea R, et al. AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma. Gastroenterology. 2022;162(3):920\u201334. https:\/\/doi.org\/10.1053\/j.gastro.2021.12.276.","journal-title":"Gastroenterology"},{"issue":"8","key":"1453_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8): EVIDoa2100070. https:\/\/doi.org\/10.1056\/EVIDoa2100070.","journal-title":"NEJM Evid."},{"issue":"5","key":"1453_CR15","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","volume":"35","author":"B Sangro","year":"2024","unstructured":"Sangro B, Chan SL, Kelley RK, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024;35(5):448\u201357. https:\/\/doi.org\/10.1016\/j.annonc.2024.02.005.","journal-title":"Ann Oncol"},{"key":"1453_CR16","unstructured":"Center for Drug Evaluation and Research. FDA approves tremelimumab in combination with durvalumab. US Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tremelimumab-combination-durvalumab-unresectable-hepatocellular-carcinoma. Accessed 16 Apr 2024."},{"issue":"3","key":"1453_CR17","doi-asserted-by":"publisher","first-page":"e512","DOI":"10.1634\/theoncologist.2019-0501","volume":"25","author":"JJ Kim","year":"2020","unstructured":"Kim JJ, McFarlane T, Tully S, Wong WWL. Lenvatinib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma: a cost-utility analysis. Oncologist. 2020;25(3):e512\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2019-0501.","journal-title":"Oncologist"},{"issue":"10","key":"1453_CR18","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.4251\/wjgo.v15.i10.1796","volume":"15","author":"D Li","year":"2023","unstructured":"Li D, Gruber SB, Iyer S, Gupta S, Tejani M. Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States. World J Gastrointest Oncol. 2023;15(10):1796\u2013806. https:\/\/doi.org\/10.4251\/wjgo.v15.i10.1796.","journal-title":"World J Gastrointest Oncol."},{"issue":"2","key":"1453_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0037","volume":"4","author":"D Su","year":"2021","unstructured":"Su D, Wu B, Shi L. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma. JAMA Netw Open. 2021;4(2): e210037. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0037.","journal-title":"JAMA Netw Open"},{"key":"1453_CR20","doi-asserted-by":"publisher","first-page":"8811018","DOI":"10.1155\/2021\/8811018","volume":"2021","author":"BM Meyers","year":"2021","unstructured":"Meyers BM, Vogel A, Marotta P, et al. The cost-effectiveness of lenvatinib in the treatment of advanced or unresectable hepatocellular carcinoma from a Canadian perspective. Can J Gastroenterol Hepatol. 2021;2021:8811018. https:\/\/doi.org\/10.1155\/2021\/8811018.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"12","key":"1453_CR21","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s40261-020-00983-7","volume":"40","author":"M Saiyed","year":"2020","unstructured":"Saiyed M, Byrnes J, Srivastava T, Scuffham P, Downes M. Cost-effectiveness of lenvatinib compared with sorafenib for the first-line treatment of advanced hepatocellular carcinoma in Australia. Clin Drug Investig. 2020;40(12):1167\u201376. https:\/\/doi.org\/10.1007\/s40261-020-00983-7.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"1453_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.11.1351.","journal-title":"Value Health."},{"issue":"1","key":"1453_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan\u2013Meier survival curves. BMC Med Res Methodol. 2021;21(1):111. https:\/\/doi.org\/10.1186\/s12874-021-01308-8.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"1453_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1177\/0145445516673998","volume":"41","author":"D Drevon","year":"2017","unstructured":"Drevon D, Fursa SR, Malcolm AL. Intercoder reliability and validity of WebPlotDigitizer in extracting graphed data. Behav Modif. 2017;41(2):323\u201339. https:\/\/doi.org\/10.1177\/0145445516673998.","journal-title":"Behav Modif"},{"key":"1453_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. https:\/\/doi.org\/10.1186\/1471-2288-12-9.","journal-title":"BMC Med Res Methodol"},{"key":"1453_CR26","unstructured":"Nice DSU technical support document 14. https:\/\/www.ncbi.nlm.nih.gov\/books\/n\/nicetechsup14\/pdf. Accessed 18 Apr 2024."},{"key":"1453_CR27","unstructured":"Extrapolating clinical evidence within economic evaluations. https:\/\/www.cadth.ca\/sites\/default\/files\/attachments\/2023-05\/MH0011-ExtrapolatingClinicalEvidenceWithinEconomicEvaluations_0.pdf. Accessed 18 Apr 2024."},{"key":"1453_CR28","unstructured":"Micromedex Red Book: patient education. Merative. https:\/\/www.merative.com\/micromedex-training-center\/red-book. Accessed 18 Apr 2024."},{"issue":"5","key":"1453_CR29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/jnci\/djx226","volume":"110","author":"KR Tringale","year":"2018","unstructured":"Tringale KR, Carroll KT, Zakeri K, Sacco AG, Barnachea L, Murphy JD. Cost-effectiveness analysis of nivolumab for treatment of platinum-resistant recurrent or metastatic squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 2018;110(5):479\u201385. https:\/\/doi.org\/10.1093\/jnci\/djx226.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"1453_CR30","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1111\/j.1440-1746.2010.06404.x","volume":"25","author":"BI Carr","year":"2010","unstructured":"Carr BI, Carroll S, Muszbek N, Gondek K. Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25(11):1739\u201346. https:\/\/doi.org\/10.1111\/j.1440-1746.2010.06404.x.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"1453_CR31","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/hep.28961","volume":"65","author":"B Cadier","year":"2017","unstructured":"Cadier B, Bulsei J, Nahon P, et al. Early detection and curative treatment of hepatocellular carcinoma: a cost-effectiveness analysis in France and in the United States. Hepatology. 2017;65(4):1237\u201348. https:\/\/doi.org\/10.1002\/hep.28961.","journal-title":"Hepatology"},{"issue":"6","key":"1453_CR32","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1001\/jamainternmed.2018.0750","volume":"178","author":"P May","year":"2018","unstructured":"May P, Normand C, Cassel JB, et al. Economics of palliative care for hospitalized adults with serious illness: a meta-analysis. JAMA Intern Med. 2018;178(6):820\u20139. https:\/\/doi.org\/10.1001\/jamainternmed.2018.0750.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"1453_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196007","volume":"13","author":"W Wong","year":"2018","unstructured":"Wong W, Yim YM, Kim A, et al. Assessment of costs associated with adverse events in patients with cancer. PLoS ONE. 2018;13(4): e0196007. https:\/\/doi.org\/10.1371\/journal.pone.0196007.","journal-title":"PLoS ONE"},{"issue":"4","key":"1453_CR34","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1016\/j.clcc.2018.08.003","volume":"17","author":"SK Cho","year":"2018","unstructured":"Cho SK, Hay JW, Barzi A. Cost-effectiveness analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer in the United States. Clin Colorectal Cancer. 2018;17(4):e751\u201361. https:\/\/doi.org\/10.1016\/j.clcc.2018.08.003.","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"1453_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jhep.2008.07.029","volume":"50","author":"K Lang","year":"2009","unstructured":"Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol. 2009;50(1):89\u201399. https:\/\/doi.org\/10.1016\/j.jhep.2008.07.029.","journal-title":"J Hepatol"},{"issue":"12","key":"1453_CR36","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1007\/s00520-013-1931-3","volume":"21","author":"C Li","year":"2013","unstructured":"Li C, Zeliadt SB, Hall IJ, et al. Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective. Support Care Cancer. 2013;21(12):3461\u20139. https:\/\/doi.org\/10.1007\/s00520-013-1931-3.","journal-title":"Support Care Cancer"},{"key":"1453_CR37","unstructured":"Archived consumer price index supplemental files. U.S. Bureau of Labor Statistics. https:\/\/www.bls.gov\/cpi\/tables\/supplemental-files\/. Accessed 19 June 2024."},{"issue":"3","key":"1453_CR38","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/hep.26221","volume":"57","author":"C Camm\u00e0","year":"2013","unstructured":"Camm\u00e0 C, Cabibbo G, Petta S, et al. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology. 2013;57(3):1046\u201354. https:\/\/doi.org\/10.1002\/hep.26221.","journal-title":"Hepatology"},{"key":"1453_CR39","unstructured":"National Institute for Clinical Excellence. Sorafenib for treating advanced hepatocellular carcinoma: Technology appraisal guidance TA474. September 6, 2017. https:\/\/www.nice.org.uk\/guidance\/TA474. Accessed 2 Oct 2024."},{"issue":"4","key":"1453_CR40","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.3747\/co.23.2244","volume":"23","author":"J Amdahl","year":"2016","unstructured":"Amdahl J, Diaz J, Park J, Nakhaipour HR, Delea TE. Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada. Curr Oncol. 2016;23(4):e340\u201354. https:\/\/doi.org\/10.3747\/co.23.2244.","journal-title":"Curr Oncol"},{"issue":"15","key":"1453_CR41","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jama.2023.1792","volume":"329","author":"PJ Neumann","year":"2023","unstructured":"Neumann PJ, Kim DD. Cost-effectiveness thresholds used by study authors, 1990\u20132021. JAMA. 2023;329(15):1312\u20134. https:\/\/doi.org\/10.1001\/jama.2023.1792.","journal-title":"JAMA"},{"issue":"10","key":"1453_CR42","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine [published correction appears in JAMA. 2016 Nov 8;316(18):1924]. JAMA. 2016;316(10):1093\u2013103. https:\/\/doi.org\/10.1001\/jama.2016.12195.","journal-title":"JAMA"},{"key":"1453_CR43","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2018","unstructured":"Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2018."},{"issue":"4","key":"1453_CR44","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro Ramos I, van Voorn GA, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349\u201361. https:\/\/doi.org\/10.1007\/s40273-015-0327-2.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1453_CR45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/13696998.2018.1552432","volume":"22","author":"G Hamdy Elsisi","year":"2019","unstructured":"Hamdy Elsisi G, Nada Y, Rashad N, Carapinha J. Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt. J Med Econ. 2019;22(2):163\u20138. https:\/\/doi.org\/10.1080\/13696998.2018.1552432.","journal-title":"J Med Econ"},{"issue":"4","key":"1453_CR46","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jceh.2018.10.003","volume":"9","author":"N Gupta","year":"2019","unstructured":"Gupta N, Verma RK, Prinja S, Dhiman RK. Cost-effectiveness of sorafenib for treatment of advanced hepatocellular carcinoma in India. J Clin Exp Hepatol. 2019;9(4):468\u201375. https:\/\/doi.org\/10.1016\/j.jceh.2018.10.003.","journal-title":"J Clin Exp Hepatol"},{"issue":"11","key":"1453_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207132","volume":"13","author":"A Shlomai","year":"2018","unstructured":"Shlomai A, Leshno M, Goldstein DA. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib: a cost-effectiveness analysis. PLoS ONE. 2018;13(11): e0207132. https:\/\/doi.org\/10.1371\/journal.pone.0207132.","journal-title":"PLoS ONE"},{"key":"1453_CR48","doi-asserted-by":"publisher","first-page":"175628481987830","DOI":"10.1177\/1756284819878304","volume":"12","author":"A Shlomai","year":"2019","unstructured":"Shlomai A, Leshno M, Goldstein DA. Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis. Therap Adv Gastroenterol. 2019;12:1756284819878304. https:\/\/doi.org\/10.1177\/1756284819878304.","journal-title":"Therap Adv Gastroenterol."},{"key":"1453_CR49","unstructured":"European Medicines Agency. Imfinzi: opinion on variation to marketing authorisation. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/variation\/imfinzi. Accessed 19 Apr 2024."},{"key":"1453_CR50","unstructured":"IMFINZI significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in Adriatic phase III trial. 2024. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/imfinzi-improved-os-and-pfs-in-limited-stage-sclc.html. Accessed 19 Apr 2024."},{"key":"1453_CR51","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2147\/JHC.S365002","volume":"9","author":"MH Storandt","year":"2022","unstructured":"Storandt MH, Mahipal A, Tella SH, Kommalapati A, Jin Z. Systemic therapy in advanced hepatocellular carcinoma: patient selection and key considerations. J Hepatocell Carcinoma. 2022;9:1187\u2013200. https:\/\/doi.org\/10.2147\/JHC.S365002.","journal-title":"J Hepatocell Carcinoma."},{"issue":"2","key":"1453_CR52","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1158\/1078-0432.CCR-23-2124","volume":"30","author":"TH Patel","year":"2024","unstructured":"Patel TH, Brewer JR, Fan J, et al. FDA approval summary: tremelimumab in combination with durvalumab for the treatment of patients with unresectable hepatocellular carcinoma. Clin Cancer Res. 2024;30(2):269\u201373. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2124.","journal-title":"Clin Cancer Res"},{"key":"1453_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.818647","volume":"8","author":"M McPhail","year":"2022","unstructured":"McPhail M, Weiss E, Bubela T. Conditional drug approval as a path to market for oncology drugs in Canada: challenges and recommendations for assessing eligibility and regulatory responsiveness. Front Med (Lausanne). 2022;8: 818647. https:\/\/doi.org\/10.3389\/fmed.2021.818647.","journal-title":"Front Med (Lausanne)."},{"issue":"5","key":"1453_CR54","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3390\/cancers13050931","volume":"13","author":"CL Chiang","year":"2021","unstructured":"Chiang CL, Chan SK, Lee SF, Choi HC. First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis. Cancers (Basel). 2021;13(5):931. https:\/\/doi.org\/10.3390\/cancers13050931.","journal-title":"Cancers (Basel)."},{"issue":"22","key":"1453_CR55","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1002\/cncr.34457","volume":"128","author":"Y Li","year":"2022","unstructured":"Li Y, Liang X, Li H, Chen X. Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: a cost-effectiveness analysis. Cancer. 2022;128(22):3995\u20134003. https:\/\/doi.org\/10.1002\/cncr.34457.","journal-title":"Cancer"},{"issue":"6","key":"1453_CR56","doi-asserted-by":"publisher","first-page":"927","DOI":"10.21037\/hbsn-22-510","volume":"11","author":"T Hatanaka","year":"2022","unstructured":"Hatanaka T, Naganuma A, Yata Y, Kakizaki S. Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma? Hepatobiliary Surg Nutr. 2022;11(6):927\u201330. https:\/\/doi.org\/10.21037\/hbsn-22-510.","journal-title":"Hepatobiliary Surg Nutr."},{"key":"1453_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b1147","volume":"338","author":"F Song","year":"2009","unstructured":"Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ. 2009;338: b1147. https:\/\/doi.org\/10.1136\/bmj.b1147.","journal-title":"BMJ"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01453-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-024-01453-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01453-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T14:59:49Z","timestamp":1739458789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-024-01453-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1453"],"URL":"https:\/\/doi.org\/10.1007\/s40273-024-01453-0","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"29 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the conduct of this study of the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Xiaomo Xiong and Jeff Jianfei Guo have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This model-based study did not involve human subjects. Thus, it was exempted from institutional review board approval by the University of Cincinnati.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data used in the study are publicly available from literature, conference abstracts, and official sources cited in the references. The models employed in the analysis are available upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Codes for the survival analysis are available upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"XX and JJG conceptualized the study design. XX constructed the model, collected and analyzed the data, and drafted the manuscript. XX supervised the study. All authors contributed to the critical revision of the manuscript for important intellectual content. All authors gave final approval for the version to be published.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":11,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}